A prospective observational study for impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy

A prospective observational study for impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy - A prospective observational study for impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018544

Enrollment

100

Registered

2015-08-05

Start date

2014-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patient who plans anticancer agent of high emetic risk 2) The patient whom an anticancer agent is not given to anticancer agent of high emetic risk in the past 3) The planned patient who gives antiemetic drugs including aprepitant or fosaprepitant and palonosetron 4) Age at the time registration is a patient 20 years or older 5) The patient who did not experience nausea and vomiting within 24 hours before giving an anticancer agent 6) Given written informed consent

Exclusion criteria

Exclusion criteria: 1) Any other inadequacy for this study 2) Presence of brain metastases 3) Hypercalcemia 4) Gastrointestinal obstruction 5) other medication or participation in studies that might modify the usual chemotherapy induced nausea and vomiting pattern or the emetogenous level of the chemotherapy regimen received

Design outcomes

Primary

Measure	Time frame
Rate of no impact on patient's QOL during 0 to 120 hours (all phase) after an anticancer agent dosage start	—

Secondary

Measure	Time frame
1) Rate of no impact on patient's QOL during 0 to 24 hours (acute phase) after an anticancer agent dosage start 2) Rate of no impact on patient's QOL during 24 to 120 hours (delay phase) after an anticancer agent dosage start 3) Complete protection rate during 0 to 24 hours (acute phase) after an anticancer agent dosage start 4) Complete protection rate during 24 to 120 hours (delay phase) after an anticancer agent dosage start	—

Measure

Time frame

1) Rate of no impact on patient's QOL during 0 to 24 hours (acute phase) after an anticancer agent dosage start 2) Rate of no impact on patient's QOL during 24 to 120 hours (delay phase) after an anticancer agent dosage start 3) Complete protection rate during 0 to 24 hours (acute phase) after an anticancer agent dosage start 4) Complete protection rate during 24 to 120 hours (delay phase) after an anticancer agent dosage start

—

Countries

Japan

Contacts

Public ContactJumpei Tokumaru

Yokohama City University Medical Center Pharmaceutical Department

toku_j@yokohama-cu.ac.jp045-261-5656

Outcome results